Imagion Biosystems Ltd
ASX:IBX
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Imagion Biosystems Ltd
ASX:IBX
|
11.7m AUD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
188.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
114.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.2B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.7B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.7B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37.8B USD |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Imagion Biosystems Ltd
Glance View
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm's principal activities include nanotechnology, biotechnology, cancer diagnostics and medical imaging using superparamagnetic relaxometry. Its MagSense technology is a functional imaging method for detecting cancers and other critical diseases. MagSense instrument uses sensitive magnetic sensors to detect the tiny bio-safe nanoparticles. MagSense nanoparticles bound to cancer cells act like a magnetic beacon to identify the presence of a tumour. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. Its PrecisionMRX nanoparticles are developed for magnetic relaxometry and other biomedical applications. The company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases. Its MagSense HER2 imaging agent is under phase I clinical study.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Imagion Biosystems Ltd is -208.5%, which is above its 3-year median of -551.6%.
Over the last 3 years, Imagion Biosystems Ltd’s Net Margin has increased from -3 035.2% to -208.5%. During this period, it reached a low of -3 035.2% on May 30, 2022 and a high of -176.6% on Dec 31, 2024.
